Use of LPC antagonist, choline, in the management of bronchial asthma.
Indian J Chest Dis Allied Sci
;
1997 Apr-Jun; 39(2): 107-13
Artigo
em Inglês
| IMSEAR
| ID: sea-29856
ABSTRACT
The present study was conducted to compare the effects of disodium cromoglycate (DSCG) and choline, a lipotropic factor, in management of bronchial asthma. Two groups taking DSCG and choline were compared between themselves and with a control group (on bronchodilators only) in a three month trial. A significant improvement in average symptoms scores was observed in all groups but was clinically significant only in the groups taking choline. Percent asymptomatic days increased in all the groups, but was not significant. The additional drug requirement decreased significantly only in the group taking choline. All groups showed an improvement in SGaw at FRC and percent fall in specific airways conductance (SGaw) at RV, but non-significant. A significant fall in bronchial hyperreactivity (BHR) was observed in the group taking choline, which was not consistent, whereas a marginal increase in BHR in the control and DSCG groups was observed. It is concluded that choline, an anti-inflammatory agent which acts by lowering lipophosphatidyl choline (LPC), plays an active role in subjective as well as functional improvement in bronchial asthma. However, a dose related response is yet to be established.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Testes de Função Respiratória
/
Asma
/
Broncodilatadores
/
Feminino
/
Humanos
/
Masculino
/
Criança
/
Colina
/
Adolescente
/
Resultado do Tratamento
Tipo de estudo:
Ensaio Clínico Controlado
Idioma:
Inglês
Revista:
Indian J Chest Dis Allied Sci
Ano de publicação:
1997
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS